Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  MUMBAI STOCK EXCHANGE  >  Dr. Reddy's Laboratories Limited    500124   INE089A01023

DR. REDDY'S LABORATORIES LIMITED

(500124)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Doctor Reddy's: Fiscal 2Q Earnings Snapshot

10/28/2020 | 05:02am EST

HYDERABAD, India (AP) _ Dr. Reddy's Laboratories Ltd. (RDY) on Wednesday reported fiscal second-quarter net income of $104 million.

On a per-share basis, the Hyderabad, India-based company said it had profit of 62 cents.

The pharmaceutical posted revenue of $666 million in the period.

Doctor Reddy's shares have risen 68% since the beginning of the year. The stock has climbed 75% in the last 12 months.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on RDY at https://www.zacks.com/ap/RDY

Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News

All news about DR. REDDY'S LABORATORIES LIMITED
12/01DR REDDY LABORATORIES : . Reddy's and RDIF commence clinical trials for Sputnik ..
BU
11/30DR REDDY LABORATORIES : . Reddy's to acquire select Anti-Allergy brands from Gle..
PU
11/28DR REDDY LABORATORIES : . Reddy's to Acquire Select Anti-Allergy Brands from Gle..
BU
11/27Pharma firm in India to make Russia's Sputnik V COVID-19 vaccine
RE
11/20DR REDDY LABORATORIES : Half yearly disclosure of related party transactions - S..
PU
11/17India pins hopes on locally-tested COVID-19 vaccines given Pfizer constraints
RE
11/16APPILI THERAPEUTICS : Reports Financial and Operational Results for Second Quart..
AQ
11/12DR REDDY LABORATORIES : Announces the Launch of Succinylcholine Chloride Injecti..
BU
11/12India's Serum says made 40 million doses of AstraZeneca's COVID vaccine, to m..
RE
11/09DR REDDY LABORATORIES : Presents Preclinical Data at SITC 2020 Demonstrating Sig..
BU
More news
Financials
Sales 2021 193 B 2 615 M 2 615 M
Net income 2021 27 597 M 374 M 374 M
Net cash 2021 10 068 M 137 M 137 M
P/E ratio 2021 29,1x
Yield 2021 0,53%
Capitalization 801 B 10 894 M 10 861 M
EV / Sales 2021 4,10x
EV / Sales 2022 3,57x
Nbr of Employees 21 650
Free-Float 68,2%
Chart DR. REDDY'S LABORATORIES LIMITED
Duration : Period :
Dr. Reddy's Laboratories Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DR. REDDY'S LABORATORIES LIMITED
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 33
Average target price 5 522,33 INR
Last Close Price 4 827,65 INR
Spread / Highest target 32,6%
Spread / Average Target 14,4%
Spread / Lowest Target -17,1%
EPS Revisions
Managers
NameTitle
Erez Israeli Chief Executive & Operating Officer
Saumen Chakraborty President, CFO & Global Head-IT
Satish Kallam Reddy Co-Chairman
Gunupati Venkateswara Prasad Co-Chairman & Managing Director
Kalpana Jaisingh Morparia Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
DR. REDDY'S LABORATORIES LIMITED67.86%10 894
JOHNSON & JOHNSON1.08%388 168
ROCHE HOLDING AG-4.59%284 650
PFIZER, INC.6.17%219 056
MERCK & CO., INC.-10.34%206 324
NOVARTIS AG-11.46%205 415